SEMAGLUTIDE MIGLIORA LA ISTOLOGIA NELLA MASH (METABOLIC ASSOCIATED STEATOHEPATITIS). IL TRIAL VS PLACEBO “ESSENCE”. RISULTATI PRELIMINARI SU 800 PAZIENTI A 2 ANNI. DA “NEJM” (NON FREE PURTROPPO)
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis Arun J. Sanyal et al. for the ESSENCE Study Group Abstract Background Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Methods In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined…

